chevron_leftBack
As of 13 June 2026, NDT Pharmaceuticals Inc. has a market cap of $133.9M USD, ranking #23594 globally and #3722 in the United States.
It ranks #2616 in the Financial Services sector, and #399 in the Financial Conglomerates industry.
Key Stats
Market Cap
$133.9MUSD
Company Profile
Country (HQ)
Sector
Financial Services
Industry
Financial Conglomerates
CEO
James Hovis
open_in_new
Website
ndtpharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -6.7% | 4.6% | -16% | -34% | -40% | 678% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NDTP
NDT Pharmaceuticals Inc
ISIN: US63948Q1058
Shares Out.:
Shares Outstanding:
160.004M1
Shares Float:
56.312M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
0.6567 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About NDT Pharmaceuticals Inc.
NDT Pharmaceuticals Inc., a biotechnology company, focuses on developing various therapies for severe neurological disorders associated with traumatic brain Injury. The company is based in Vienna, Virginia.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: ARCC
|
$13.41B
10K%
|
11.5
|
|
TSX: BBUC
|
$6.77B
5K%
9.46B CAD
|
-
|
|
NYSE: OBDC
|
$5.6B
4K%
|
9.1
|
|
NYSE: HASI
|
$5.22B
4K%
|
28.7
|
|
NYSE: MAIN
|
$4.84B
4K%
|
9.7
|
|
NASDAQ: GBDC
|
$3.51B
3K%
|
10.7
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
STO: INVE-A
|
$120.04B
90K%
1.14T SEK
|
5.9
|
|
KRX: 402340
|
$71.97B
54K%
109.46T KRW
|
12.5
|
|
BVMF: ITSA3
|
$30.93B
23K%
157.1B BRL
|
9.5
|
|
STO: INDU-A
|
$21.94B
16K%
207.94B SEK
|
5.2
|
|
TWSE: 2887
|
$18.94B
14K%
598.03B TWD
|
12.6
|
|
AMS: HAL
|
$17.79B
13K%
15.4B EUR
|
9.6
|
chevron_leftBack